Jump to navigation Jump to search
This image is provided by the National Library of Medicine.

WikiDoc Resources for Delamanid


Most recent articles on Delamanid

Most cited articles on Delamanid

Review articles on Delamanid

Articles on Delamanid in N Eng J Med, Lancet, BMJ


Powerpoint slides on Delamanid

Images of Delamanid

Photos of Delamanid

Podcasts & MP3s on Delamanid

Videos on Delamanid

Evidence Based Medicine

Cochrane Collaboration on Delamanid

Bandolier on Delamanid

TRIP on Delamanid

Clinical Trials

Ongoing Trials on Delamanid at Clinical

Trial results on Delamanid

Clinical Trials on Delamanid at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Delamanid

NICE Guidance on Delamanid


FDA on Delamanid

CDC on Delamanid


Books on Delamanid


Delamanid in the news

Be alerted to news on Delamanid

News trends on Delamanid


Blogs on Delamanid


Definitions of Delamanid

Patient Resources / Community

Patient resources on Delamanid

Discussion groups on Delamanid

Patient Handouts on Delamanid

Directions to Hospitals Treating Delamanid

Risk calculators and risk factors for Delamanid

Healthcare Provider Resources

Symptoms of Delamanid

Causes & Risk Factors for Delamanid

Diagnostic studies for Delamanid

Treatment of Delamanid

Continuing Medical Education (CME)

CME Programs on Delamanid


Delamanid en Espanol

Delamanid en Francais


Delamanid in the Marketplace

Patents on Delamanid

Experimental / Informatics

List of terms related to Delamanid

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Delamanid (USAN, codenamed OPC-67683) is an experimental drug for the treatment of multi-drug-resistant tuberculosis. It works by blocking the synthesis of mycolic acids in Mycobacterium tuberculosis, the organism which causes tuberculosis, thus destabilising its cell wall. In phase II clinical trials, the drug was used in combination with standard treatments, such as four or five of the drugs ethambutol, isoniazid, pyrazinamide, rifampicin, aminoglycoside antibiotics, and quinolones. Healing rates (measured as sputum culture conversion) were significantly better in patients who additionally took delamanid. The European Medicines Agency (EMA) recommended conditional marketing authorization for delamanid in adults with multidrug-resistant pulmonary tuberculosis without other treatment options because of resistance or tolerability. The EMA considered the data show that the benefits of delamanid outweigh the risks, but that additional studies were needed on the long-term effectiveness.

See also